<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65092">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02258529</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-313-1414</org_study_id>
    <nct_id>NCT02258529</nct_id>
  </id_info>
  <brief_title>Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma</brief_title>
  <official_title>A Phase 2, Single Arm Study Evaluating the Safety and Efficacy of Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the overall response rate (ORR) and complete response (CR) rate to
      treatment with idelalisib in combination with rituximab in participants with follicular
      lymphoma (FL) and small lymphocytic lymphoma (SLL) who have not received prior treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>ORR is defined as the proportion of subjects who achieve a CR, or partial response (PR) during idelalisib treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, serious adverse events, abnormalities in physical findings, or laboratory abnormalities</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>This composite endpoint will evaluate the overall safety profile of idelalisib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade ≥ 3 increase in transaminase elevations</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>The rate of Grade ≥ 3 transaminase elevations is defined as the number of subjects with transaminase elevations ≥ Grade 3, who have been on treatment ≥ 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>Time to response (TTR) is defined as the interval from the start of idelalisib treatment to the first documentation of CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>Duration of Response (DOR) is defined as the interval from the first documentation of CR or PR to the earlier of the first documentation of disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>Progression-free survival (PFS) is defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Idelalisib trough and peak plasma concentrations</measure>
    <time_frame>Predose and 1.5 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in health-related quality of life</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>Changes in health-related quality of life will be reported by participants using the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>Overall survival (OS) is defined as the time interval from the start of idelalisib treatment to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Idelalisib + Biological/Vaccine: Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>Idelalisib tablets administered orally twice daily</description>
    <arm_group_label>Idelalisib + Biological/Vaccine: Rituximab</arm_group_label>
    <other_name>Zydelig®</other_name>
    <other_name>GS-1101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab administered intravenously according to prescribing information</description>
    <arm_group_label>Idelalisib + Biological/Vaccine: Rituximab</arm_group_label>
    <other_name>Rituxan®</other_name>
    <other_name>MabThera®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of B-cell lymphoma

          -  No previous systemic treatment for lymphoma

          -  Subject demonstrates need for treatment for lymphoma

          -  Ann-Arbor Stage 2 (noncontiguous), 3, or 4 disease

          -  Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy

          -  Adequate performance status

          -  Required baseline laboratory data within protocol-specified parameters

        Exclusion Criteria:

          -  Known history of transformed lymphoma or diffuse large cell lymphoid malignancy

          -  Known history of, or clinically apparent, central nervous system (CNS) lymphoma or
             leptomeningeal lymphoma

          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
             enrollment

          -  Known history of drug-induced liver injury, chronic active hepatitis B (HBV), chronic
             active hepatitis C (HCV), alcoholic liver disease, non-alcoholic steatohepatitis,
             cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing
             extrahepatic obstruction caused by cholelithiasis

          -  Ongoing inflammatory bowel disease

          -  Known human immunodeficiency virus (HIV) infection

          -  History of prior allogeneic bone marrow progenitor cell or solid organ
             transplantation

          -  Ongoing immunosuppressive therapy, including systemic corticosteroids (&gt; 10 mg
             prednisone or equivalent/day) with the exception of the use of topical, enteric, or
             inhaled corticosteroids as therapy for comorbid conditions and systemic steroids for
             autoimmune anemia and/or thrombocytopenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Abella, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Agnes Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Cancer Care, LLP</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prarie Lakes Health Care Systems, Inc.</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 17, 2016</lastchanged_date>
  <firstreceived_date>October 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Indolent Non-Hodgkin Lymphoma</keyword>
  <keyword>FL</keyword>
  <keyword>SLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Idelalisib</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
